Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Neurology"
DOI: 10.1007/s00415-025-13300-z
Abstract: Sphingosine-1-phosphate (S1P) receptor modulators, regulating the S1P/S1PR pathway, lead to lymphocyte sequestration in lymphoid organs, which results in peripheral lymphopenia. This study evaluates the degree of lymphopenia induced by S1P modulators in people with Multiple… read more here.
Keywords: s1p receptor; lymphopenia; siponimod; receptor modulators ... See more keywords
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-021-01019-9
Abstract: The aim of this study was to characterize the relationship between ponesimod plasma concentrations and the temporal evolution of lymphocyte counts in multiple sclerosis (MS) patients. Population pharmacokinetic (PK) and PK/pharmacodynamic (PD) models were developed… read more here.
Keywords: lymphocyte counts; ponesimod; total lymphocyte; clinically relevant ... See more keywords
Ponesimod: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01523-z
Abstract: Ponesimod (PONVORY™) is an orally administered selective sphingosine-1-phosphate (S1P) receptor 1 (S1P1) agonist being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson for the treatment of multiple sclerosis (MS). Based on the results… read more here.
Keywords: first approval; ponesimod; ponesimod first;
Ponesimod for the treatment of relapsing multiple sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2020.1799977
Abstract: ABSTRACT Introduction Multiple Sclerosis (MS) is an immune-mediated, complex, chronic inflammatory, and neurodegenerative disease of the central nervous system. Among the several therapeutic options developed over the last decade for relapsing MS (RMS), fingolimod, a… read more here.
Keywords: multiple sclerosis; ponesimod; ponesimod treatment; treatment relapsing ... See more keywords
Ponesimod protects against neuronal death by suppressing the activation of A1 astrocytes in early brain injury after experimental subarachnoid hemorrhage
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Neurochemistry"
DOI: 10.1111/jnc.15457
Abstract: As an important initiator and responder of brain inflammation in the central nervous system (CNS), astrocytes transform into two new reactive phenotypes with changed morphology, altered gene expression and secretion profiles, termed detrimental A1 and… read more here.
Keywords: ponesimod; early brain; subarachnoid hemorrhage; brain injury ... See more keywords
Ponesimod to treat multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2021 at "Drugs of today"
DOI: 10.1358/dot.2021.57.12.3353166
Abstract: Ponesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the… read more here.
Keywords: ponesimod; treat multiple; ponesimod treat; multiple sclerosis ... See more keywords